ZYBT
Zhengye Biotechnology Holding LtdZhengye Biotechnology Holding Ltd reported revenue of CNY 116.36M in its most recent fiscal year, down 37.6% on the year before. It kept -60.0% of that as net income, and generated CNY 12.32M of free cash flow. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -37.6% | 12.8% | 153 / 159 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -23.5% | 12.2% | 141 / 151 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | Not reported | 12.5% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -2.6% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 2.8% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 1.9% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | -55.1% | -4.1% | 46 / 56 |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 1.4% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 20.5% | 70.7% | 100 / 106 |
Operating margin Operating income as a share of revenue. | -60.6% | -15.3% | 105 / 152 |
Net margin Net income as a share of revenue. | -60.0% | -13.0% | 119 / 163 |
Free cash flow margin Free cash flow as a share of revenue. | 10.6% | -2.0% | 46 / 144 |
Return on equity Net income divided by shareholder equity. | -27.9% | -14.2% | 101 / 164 |
Return on assets Net income divided by total assets. | -16.0% | -9.5% | 113 / 188 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -26.6% | -6.1% | 87 / 121 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.04x | 0.43x | 15 / 86 |
Current ratio Current assets over current liabilities. | 1.14x | 2.96x | 167 / 189 |
Quick ratio Current assets excluding inventory, over current liabilities. | 0.82x | 2.58x | 172 / 189 |
Interest coverage Operating income divided by interest expense. | -20.74x | -0.74x | 82 / 96 |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | CNY 116.36M | CNY 186.36M | CNY 211.65M | CNY 260.27M |
| Gross profit | CNY 23.87M | CNY 91.30M | CNY 117.51M | CNY 147.88M |
| Operating income | -CNY 70.51M | CNY 16.44M | CNY 44.99M | CNY 65.83M |
| Net income | -CNY 69.78M | CNY 11.31M | CNY 31.46M | CNY 46.73M |
| EPS (diluted) | — | CNY 0.25 | CNY 0.69 | CNY 1.02 |
| Operating cash flow | CNY 13.33M | CNY 41.05M | CNY 48.18M | CNY 17.34M |
| Capital expenditure | CNY 1.01M | CNY 13.59M | CNY 7.40M | CNY 27.33M |
| Free cash flow | CNY 12.32M | CNY 27.46M | CNY 40.79M | -CNY 9.99M |
| Total assets | CNY 436.47M | CNY 493.25M | CNY 499.89M | — |
| Shareholder equity | CNY 249.85M | CNY 283.96M | CNY 272.85M | CNY 356.87M |
| Total debt | CNY 10.25M | CNY 11.99M | CNY 89.85M | — |
| Cash | CNY 50.33M | CNY 18.60M | CNY 15.07M | CNY 9.75M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Amounts are in CNY, as the company reports them. Nothing here is converted to dollars, so these figures cannot be compared directly against a company reporting in another currency. Margins, returns and other ratios are unaffected.
Source
Figures come from Zhengye Biotechnology Holding Ltd’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 20-F filed Apr 28, 2026. View filings on EDGAR.